VXRT News and Press, Vaxart Inc. From 07/26/21

InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’ll admit, it’s hard for me not to be massively bullish on California-based biotech company Vaxart  (NASDAQ: VXRT ) stock. Source: Ascannio / Shutterstock.com With the exception of occasional ...

On July 22, both The Jerusalem Post and Forbes reported that Oravax Medical's oral COVID vaccine candidate is about to begin a phase 1 trial in Israel. While Israel is said to be "first in world" to test "Oravax" oral COVID vaccine, Vaxart, a US-based company, has completed a phase 1 ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Stick around in the business of assessing investment opportunities, and you’re bound to make your fair share of calls that go awry . That’s exactly what happened with my early June take on Vaxart (NASDAQ: ...

Shares of Vaxart (NASDAQ: VXRT) jumped 31.2% through the first half of 2021, according to data from S&P Global Market Intelligence . That price at the end of July doesn't even begin to tell the story of those six months. Over the period, the stock rose as much as 300% and fe...

Shares of a clutch of healthcare companies involved directly or tangentially in the fight against the coronavirus were doing very well on Monday. Moderna (NASDAQ: MRNA) , for one, was up by nearly 10% in midafternoon trading, while Co-Diagnostics (NASDAQ: CODX) was trailing ...

gopixa/iStock via Getty Images Many of the coronavirus test makers and vaccine developers are trading higher in morning hours while the U.S. stocks have trended lower amid concerns over a spike in COVID-19 infections and deaths across the country after weeks of decline. Moderna ([[MRNA]] +6.5...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxart  (NASDAQ: VXRT ) has been one of the most volatile names in the biotech sector in the last 12 months. One reason is that it’s still trying to participate in the Covid-19 vaccine race. Anothe...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Several recent news items have improved my confidence in Vaxart (NASDAQ: VXRT ) stock. Specifically, another columnist provided additional evidence that the company’s Covid-19 vaccine candidate could be effecti...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Other than a massive trading spike in Feb. 2020 to $24.90, Vaxart (NASDAQ: VXRT ) has gone nowhere. A mid-June upgrade from Piper Sandler to an “overweight” rating temporarily lifted VXRT stock, but it...

Vaxart (VXRT) has signed an exclusive worldwide licensing agreement with Altesa Biosciences to develop and commercialize patented formulation of Vapendavir in a deal worth as much as $130M.Share up more than 5% premarket.Vaxart is eligible to receive up to $130M in development and c...